Laura M. Clague's most recent trade in Standard BioTools Inc was a trade of 42,571 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 15, 2022.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Standard BioTools Inc | Laura M. Clague | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 42,571 | 42,571 | - | - | Stock Option (Right to Buy) | |
| Standard BioTools Inc | Laura M. Clague | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 30,914 | 78,415 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Laura M. Clague | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 21.51 per share. | 10 May 2022 | 1,375 | 35,655 (0%) | 0% | 21.5 | 29,576 | Common Stock |
| Travere Therapeutics Inc | Laura M. Clague | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 21.51 per share. | 10 May 2022 | 825 | 37,030 (0%) | 0% | 21.5 | 17,746 | Common Stock |
| Genasys Inc | Laura M. Clague | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.33 per share. | 27 Apr 2022 | 50,000 | 284,311 (0%) | 0% | 1.3 | 66,500 | Common Stock |
| Genasys Inc | Laura M. Clague | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Apr 2022 | 50,000 | 0 | - | - | Stock Option | |
| Genasys Inc | Laura M. Clague | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2022 | 30,000 | 234,311 (0%) | 0% | - | Common Stock | |
| Genasys Inc | Laura M. Clague | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.16 per share. | 23 Feb 2022 | 20,000 | 218,027 (0%) | 0% | 2.2 | 43,200 | Common Stock |
| Genasys Inc | Laura M. Clague | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2022 | 20,000 | 0 | - | - | Stock Option | |
| Genasys Inc | Laura M. Clague | Director | Sale of securities on an exchange or to another person at price $ 3.14 per share. | 23 Feb 2022 | 13,716 | 204,311 (0%) | 0% | 3.1 | 43,068 | Common Stock |
| Travere Therapeutics Inc | Laura M. Clague | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 39,360 | 39,360 | - | - | Employee stock option (right to buy) | |
| Travere Therapeutics Inc | Laura M. Clague | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 9,840 | 9,840 | - | - | Performance-based restricted stock units | |
| Travere Therapeutics Inc | Laura M. Clague | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 9,840 | 39,093 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Laura M. Clague | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 8,000 | 8,000 | - | - | Performance-based restricted stock units | |
| Travere Therapeutics Inc | Laura M. Clague | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 27.40 per share. | 31 Jan 2022 | 1,238 | 37,855 (0%) | 0% | 27.4 | 33,921 | Common Stock |
| Travere Therapeutics Inc | Laura M. Clague | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 24.98 per share. | 24 Jan 2022 | 2,063 | 29,253 (0%) | 0% | 25.0 | 51,534 | Common Stock |
| Travere Therapeutics Inc | Laura M. Clague | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jan 2022 | 7,500 | 38,816 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Laura M. Clague | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 27.40 per share. | 10 Jan 2022 | 7,500 | 31,316 (0%) | 0% | 27.4 | 205,500 | Common Stock |
| Travere Therapeutics Inc | Laura M. Clague | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Aug 2021 | 4,500 | 32,723 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Laura M. Clague | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 17.12 per share. | 13 Aug 2021 | 1,407 | 31,316 (0%) | 0% | 17.1 | 24,085 | Common Stock |
| Standard BioTools Inc | Laura M. Clague | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2021 | 15,402 | 15,402 | - | - | Stock Option (Right to Buy) | |
| Standard BioTools Inc | Laura M. Clague | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2021 | 10,342 | 47,501 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Laura M. Clague | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 19.14 per share. | 11 May 2021 | 2,000 | 30,223 (0%) | 0% | 19.1 | 38,280 | Common Stock |
| Travere Therapeutics Inc | Laura M. Clague | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 19.46 per share. | 11 May 2021 | 2,000 | 28,223 (0%) | 0% | 19.5 | 38,920 | Common Stock |
| Genasys Inc | Laura M. Clague | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2021 | 27,883 | 168,027 (0%) | 0% | - | Common Stock | |
| Genasys Inc | Laura M. Clague | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2021 | 20,000 | 0 | - | - | Stock Option | |
| Genasys Inc | Laura M. Clague | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.02 per share. | 10 Mar 2021 | 20,000 | 175,600 (0%) | 0% | 2.0 | 40,400 | Common Stock |
| Genasys Inc | Laura M. Clague | Director | Sale of securities on an exchange or to another person at price $ 7.42 per share. | 10 Mar 2021 | 5,456 | 170,144 (0%) | 0% | 7.4 | 40,465 | Common Stock |
| Standard BioTools Inc | Laura M. Clague | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2021 | 9,803 | 37,159 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Laura M. Clague | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 31.41 per share. | 05 Feb 2021 | 2,250 | 34,473 (0%) | 0% | 31.4 | 70,673 | Common Stock |
| Travere Therapeutics Inc | Laura M. Clague | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 31.58 per share. | 05 Feb 2021 | 2,250 | 32,223 (0%) | 0% | 31.6 | 71,055 | Common Stock |
| Travere Therapeutics Inc | Laura M. Clague | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2021 | 4,500 | 36,723 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Laura M. Clague | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 28.91 per share. | 03 Feb 2021 | 2,500 | 33,348 (0%) | 0% | 28.9 | 72,275 | Common Stock |
| Travere Therapeutics Inc | Laura M. Clague | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 28.91 per share. | 03 Feb 2021 | 1,125 | 32,223 (0%) | 0% | 28.9 | 32,524 | Common Stock |
| Travere Therapeutics Inc | Laura M. Clague | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2021 | 5,000 | 39,473 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Laura M. Clague | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 30.75 per share. | 31 Jan 2021 | 2,500 | 36,973 (0%) | 0% | 30.8 | 76,875 | Common Stock |
| Travere Therapeutics Inc | Laura M. Clague | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 30.75 per share. | 31 Jan 2021 | 1,125 | 35,848 (0%) | 0% | 30.8 | 34,594 | Common Stock |
| Travere Therapeutics Inc | Laura M. Clague | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jan 2021 | 57,500 | 57,500 | - | - | Employee stock option (right to buy) | |
| Travere Therapeutics Inc | Laura M. Clague | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jan 2021 | 15,000 | 34,473 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Laura M. Clague | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Nov 2020 | 7,500 | 26,973 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Laura M. Clague | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 22.72 per share. | 23 Nov 2020 | 3,750 | 19,473 (0%) | 0% | 22.7 | 85,200 | Common Stock |
| Travere Therapeutics Inc | Laura M. Clague | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 23.86 per share. | 23 Nov 2020 | 3,750 | 23,223 (0%) | 0% | 23.9 | 89,475 | Common Stock |
| Travere Therapeutics Inc | Laura M. Clague | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 23.98 per share. | 16 Nov 2020 | 7,500 | 19,473 (0%) | 0% | 24.0 | 179,813 | Common Stock |
| Travere Therapeutics Inc | Laura M. Clague | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Nov 2020 | 15,000 | 34,473 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Laura M. Clague | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 23.61 per share. | 11 Nov 2020 | 7,500 | 26,973 (0%) | 0% | 23.6 | 177,071 | Common Stock |
| Travere Therapeutics Inc | Laura M. Clague | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 18.48 per share. | 23 Sep 2020 | 1,500 | 19,473 (0%) | 0% | 18.5 | 27,720 | Common Stock |
| Travere Therapeutics Inc | Laura M. Clague | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Sep 2020 | 3,000 | 22,473 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Laura M. Clague | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 18.59 per share. | 18 Sep 2020 | 1,500 | 20,973 (0%) | 0% | 18.6 | 27,885 | Common Stock |